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Abstract
Objective Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in
endurance running and by elite athletes. We examined the pattern of use of
NSAIDs, the purpose of use and knowledge of the adverse effects of NSAID
use in a population of recreational runners at Parkrun UK.
Methods An online observational non-interventional cross-sectional survey of
Parkrun UK participants being over the age of 18, on Parkrun UK’s mailing
list, and residing in the UK.
Key Findings Runners (n = 806) had a high use of NSAIDs in the past
12 months (87.8%). The average age of respondents was 48.39 years. There was
a significant association between those taking an oral NSAID in the last twelve
months and those with a sporting injury (v2 = 10.89, df = 1, n = 797,
P = 0.001). Ibuprofen was the most commonly used NSAID (81.1%). A third
of runners had experienced an adverse drug reaction associated with NSAIDs,
usually gastrointestinal. Half of runners used NSAIDs with no advice, and
patient information leaflets were the most common source for those that had
advice. Ninety-four per cent of runners would like more information on the
harms and benefits of NSAIDs.
Conclusions Some recreational runners have a high use of NSAIDs, which is
chronic in nature and a potential health risk. Recreational runners want more
information on the harms and benefits of NSAIDs. Race event organizers
should provide evidence-based advice on the use of NSAIDs.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are
readily available over the counter, without prescription.
They have a wide range of action including analgesic,
anti-inflammatory and antipyretic properties,[1] most
causing non-selective inhibition of cyclooxygenase isoen-
zymes 1 and 2. Their analgesic and anti-inflammatory
properties are made use of by both professional and ama-
teur athletes across all sports and levels of competition.[2]
Use of NSAIDs is not prohibited by the World Anti-Dop-
ing Agency.[3] NSAIDs are consistently the most declared
medication on doping control forms at the Olympics,
Paralympics and FIFA World Cup tournaments.[4]
Concern about the potential of analgesics to provide an
ergogenic effect remain,[5] and their usage may be
indicative of a doping attitude of mind.[6] Their use is
not without risk of harms, with the established risks of
NSAIDs, such as acute renal impairment and gastroin-
testinal problems, potentially heightened when used by
athletes during endurance events. Specific risks such as
hyponatraemia can also occur, with variables such as
hydration and temperature modifying the risk.[7] NSAIDs
are also associated with a dose-related risk of cardiovascu-
lar events.[8]
Between 2009 and 2014 marathon participation
increased worldwide by 13.25%, with average completion
times indicating a high proportion of non-elite athletes.[9]
This more diverse range of runners, with a wider range of
co-morbidities, may include individuals more at risk from
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NSAID adverse effects, and the use of analgesics before a
marathon appears associated with adverse effects.[10]
NSAID use is high in other endurance athletes. Iron-
man professional triathletes are high users of NSAIDs,
with injury prevention, fatigue, and pain prevention and
relief cited as reasons for use.[11] These perceived benefits
have been questioned[12] with NSAID usage resulting in
increased harms with minimal benefit.[13] However, it is
possible that the use of NSAIDs may enable participation
in exercise. How NSAIDs are used by recreational runners
is unknown. In the UK, only ibuprofen and naproxen are
available as oral preparations without prescription, with
naproxen being sold only for the relief of period pain.
The aim of this study was to explore the pattern of use of
NSAIDs (both prescribed and over-the-counter), the pur-
pose of use and knowledge of the adverse effects of oral
NSAID use in a population of recreational runners.
Methods
The study was an observational non-interventional cross-
sectional survey, conducted using a self-completed online
questionnaire distributed to runners online via Parkrun
UK.[14] Parkrun UK organises free to enter 5 km runs
every Saturday in the UK. Founded in 2004, it has 593
different locations in the UK, with 130 000 completed
runs to date, with over 1.9 million people, of all running
abilities,[15] having participated in at least 1 event.
The self-completed questionnaire was informed by a
review of the current literature and piloted with sports
medicine doctors (n = 5), physiotherapists (n = 4), phar-
macists (n = 4) and runners (n = 10) to check face valid-
ity. The survey consisted of demographics, general NSAID
use, history of sporting injury, use of NSAIDS before,
during, and after exercise, reasons for taking NSAIDs, and
adverse effects of NSAIDs. A copy of the survey instru-
ment is provided as Appendix S1. The questionnaire was
also assessed by Parkrun UK. Some minor changes were
implemented as a result of this.
Inclusion criteria were as follows: participants being
over the age of 18, on Parkrun UK’s mailing list, and
residing in the UK. The questionnaire was hosted on Jisc
Online Surveys.[16] The survey was advertised in the Park-
run UK newsletter and was open from the 31st of Octo-
ber 2016 to the 30th of November 2016. No incentive was
given for participation. Participants remained anonymous,
with no identifiable data requested. Ethical approval was
granted by both Queen Mary’s University (QMREC1484)
and Birmingham University’s School of Pharmacy
Research Ethics Committee (2017). Consent was given by
questionnaire completion.
Data were imported into Statistical Package for Social
Scientists for data analysis.[17] Non-UK survey responses
were removed, along with non-responses with major data
absence. Statistical analysis included Pearson’s chi-squared
test (v2), a P value of less than 0.05 was accepted as sta-
tistically significant in all tests.
Results
There were 806 responses suitable for analysis, after
removal of 14 non-UK responses and 5 responses with
major data absence. Due to the method of recruitment,
no reliable response rate can be calculated. The overall
mean age of respondents was 48.39 (SD = 12.39, range of
18–82 years), with a roughly even gender split (female
46%) (Table 1). Male participants reported higher weekly
running mileage than women (Pearson v2 = 19.153,
df = 6, n = 804 P = 0.004), with the modal reported dis-
tance per week being in the range of 11 to 20 km per
week. There was a significant association between injury
and distance covered in a week (Pearson v2 = 15.46,
df = 5, n = 682 P = 0.009), with 70% (n = 557) having a
sporting injury in the past 12 months.
The majority of respondents (87.8%, n = 708) indi-
cated they had used oral NSAIDs in the past 12 months
with no difference between gender, distance run per week
or membership of an athletic club. There was a significant
association between those that had taken an oral NSAID
in the last 12 months and those that had a sporting injury
Table 1 Characteristics and NSAID use of respondents
Mean age 48.39 (SD = 12.39, range of
18-82 years)
Mean Male age (n = 394) 50.46 years (SD = 12.29. range of
18-82)
Mean Female age (n = 410) 46.44 years (SD = 12.19. range of
18-79)
Running Club Member 381 (48%)
What distance do you cover a week?
5 km (3.1 miles) or less 54 (6.7%)
6–10 km (3.7–6.2 miles) 121 (15%)
1120 km (6.3–12.9 miles) 244 (30.3%)
21–30 km (13–19.2 miles) 175 (21.8%)
31–40 km (19.3–25.4 miles) 106 (13.2%)
41–50 km (25.5–31 miles) 43 (5.3%)
50 km (31.1 miles) or more 61 (7.6%)
Sporting injury in the past
12 months
Yes: 557 (70%) (n = 557)
No: 240 (30%)
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2 The use of oral NSAIDs by recreational runners
in the past 12 months (v2 = 10.89, df = 1, n = 797,
P = 0.001).
Of the 697 NSAID users who could identify the specific
NSAID they used, ibuprofen was the most commonly
used (79.8%), followed by naproxen (11%), and diclofe-
nac (3.4%), with minor use of aspirin, celecoxib, etori-
coxib and meloxicam (Table 1). Twenty-four per cent
(n = 171) of NSAID users used oral NSAIDs on prescrip-
tion for a non-exercise-related medical condition.
Twenty-four (3.4%) of NSAID users reported that they
had exceeded the recommended daily dose of NSAIDs,
75% of whom were male.
Of runners who had taken NSAIDs in the past
12 months, 693 (98%) supplied information on NSAID
consumption over the past month. 70.7% had not taken an
oral NSAID more than for 7 days in the last month, with
13.1% taking them for more than 15 days (Table 2). Those
using ibuprofen used it less frequently than other NSAID
users with only 2.7% taking ibuprofen for more than
21 days in the last 28 days, compared to 25% of those that
took diclofenac and 27.3% of those that took naproxen.
Oral NSAID usage before, during and after running
varied with 57% of respondents having taken NSAIDs
before a run/race, 11% during, and 67.7% afterwards.
Women were more likely to use NSAIDs after a run or
race (73%) than men (62%). As the longest event distance
increased, the use of NSAIDs during races increased
(Table 3). Respondent’s reasons for using NSAIDs before,
during and after a race/run varied (Table 4).
Thirty-two per cent (n = 234) of respondents experi-
enced a suspected adverse drug reaction (ADR) a result of
NSAID use, including gastrointestinal discomfort
(n = 99), heart burn (n = 67), nausea and vomiting
(n = 34), diarrhoea (n = 11) and gastrointestinal bleeding
(n = 11). Over half of respondents were aware of the risk
of gastrointestinal ADRs (Table 5), few were aware of the
potential that NSAIDs may delay recovery time from
exercise or an injury. Approximately 1 in 10 respondents
were unaware of any adverse effects.
A number of respondents had pre-existing contra-indi-
cations or cautions to NSAID use: 115 NSAID users had
a diagnosis of asthma, 30 had a history of gastrointestinal
bleeding or ulcers, and 6 had inflammatory bowel disease.
Patient information leaflets (PILs) are the most com-
mon source of information (n = 104), followed by doc-
tors (n = 95), physiotherapists (n = 80), the Internet
(n = 66), friends and family (n = 61), pharmacists
(n = 51), coaches (n = 9) and osteopaths/podiatrists
(n = 5). Nine runners were healthcare professionals.
Many consulted no information sources about NSAIDs
Table 2 Self-reported NSAID consumption over past 28 days by NSAID
NSAID
In the past four weeks, on approximately how many days have you taken oral NSAIDs?
None 1–7 days 8–14 days 15–21 days 22–28 days
Total
nn % n % n % n % n %
Ibuprofen 124 22.1 306 54.4 91 16.2 26 4.6 15 2.7 562
Naproxen 11 14.3 21 27.3 15 19.5 9 11.7 21 27.3 77
Diclofenac 3 12.5 11 45.8 3 12.5 1 4.2 6 25.0 24
Aspirin 1 6.7 9 60.0 1 6.7 0 0.0 4 26.7 15
Celecoxib 1 16.7 1 16.7 0 0.0 0 0.0 4 66.7 6
Etoricoxib 1 20.0 1 20.0 1 20.0 1 20.0 1 20.0 5
Meloxicam 0 0.0 0 0.0 1 25.0 1 25.0 2 50.0 4
Total 141 20.3 349 50.4 112 16.2 38 5.5 53 7.6 693
Table 3 Before, during and after run/race NSAID use by longest race distance
Longest event the person
participated in
Do you ever take oral
NSAIDs BEFORE a run or
race?
Do you ever take oral
NSAIDs DURING a run
or race?
Do you ever take
NSAIDs AFTER a run or
race?
Yes Yes Yes
n % n % n %
None (n = 35) 19 54.3 3 8.6 24 68.6
5K (n = 184) 104 56.5 6 3.3 122 68.5
1OK (n = 201) 109 54.8 8 4.0 134 67.0
Half-Marathon (n = 98) 68 68.7 16 16.3 63 64.9
Marathon (n = 246) 137 56.1 43 17.5 167 68.7
Ultra (n = 36) 18 50.0 12 33.3 25 69.4
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(n = 393). A majority of respondents (795, 94.2%) indi-
cated that they would read information about the benefits
and risks of using NSAIDS during exercise if provided to
them.
Discussion
There is a high usage of NSAIDs in this sample of Park-
run UK participants, with nearly 9 out of 10 respondents
having used an NSAID in the last year. Eight out of ten
included NSAID use in the 28 days prior to completion
of the survey. Self-reported use of NSAIDs around race
events (pre, during and after) was similar to found in
other studies.
Limitations
Runners sampled were self-selecting, and therefore, our
study may over-estimate NSAID usage and injury rates
through selection bias. Despite the large number of active
UK park run attendees, the absolute number of respon-
dents might reflect that non-NSAID users did not partici-
pate, skewing the data. Our study may have also attracted
those more prone to injury, reflected in the older age pro-
file of respondents (mean age of 48), although Parkrun UK
is known to attract a high percentage of older runners.[15]
Our survey did not allow multiple NSAID entry, so
potentially dangerous double-dosing with multiple
NSAIDs was not detected. Doses of single NSAIDs
exceeding the recommended dosage may have been
underestimated, since judgements on dosage were left to
respondents. The reports of suspected adverse drug reac-
tions were self-reported, and we cannot provide definitive
proof of causality.
Our project design was not based on a specific running
event, compared to the majority of the published survey
data. However, a strength of the data is that it provides
information on a recreational running community across
a range of activity levels and demographics, and is argu-
ably a fairer representation of the general recreational
running population, compared to other more specialist
event-based surveys.
NSAID usage
Ibuprofen was the most common NSAID used in our
study, reflecting that in the United Kingdom only ibupro-
fen, naproxen and aspirin are available without prescrip-
tion. Previous studies have shown diclofenac to be the
most commonly used by runners,[10,18] but such use is
declining following awareness of a higher risk of cardiac
ADRs with diclofenac.[19] Between September 2014 and
August 2019 prescribing of oral diclofenac sodium fell by
60%.[20] The higher use of diclofenac and naproxen in
the past month, compared to ibuprofen, may indicate
these are prescribed for chronic conditions and therefore
are more likely to be used regularly.
High levels of NSAID use have been reported in ama-
teur athletic club members,[21] but most evidence comes
from endurance running events. Mohseni and colleagues
reported 40% of participants in a half-marathon/mara-
thon event used NSAIDs regularly, with 17% using on the
morning of the event, or during the event.[22] Tillander
and colleagues reported that 42% of runners at a mara-
thon event used NSAIDs in the 12 months leading up to
the event.[23] A small survey of London Marathon partici-
pants found 46% planned to take an NSAID during the
marathon, with 34% having taken an NSAID in the
morning.[24] A large study of the Bonn marathon in Ger-
many found that 49% of runners had used analgesics,
mainly diclofenac and ibuprofen.[10] A more recent study
Table 4 Reasons for taking an NSAID before, during, and after a run or race event
Reason for use of NSAID before a race
event (n = 240)
Reason for use of NSAID during a race
event (n = 43)
Reason for use of NSAID after a race event
(n = 352)
(1) To reduce inflammation/swelling 58%
(2) To increase pain tolerance 42.7%
(3) To continue running through an injury
42.7%
(4) To treat an injury 25.1%
(5) To reduce muscle soreness 22.7%
(6) To treat chronic pain or ongoing medi-
cal issues 3.9%
(1) To increase pain tolerance 54.1%
(2) To reduce inflammation/swelling 50.6%
(3) To continue running through an injury
49.4%
(4) To treat chronic pain or ongoing medi-
cal issues 24.7%
(5) To reduce muscle soreness 21.2%
(6) To treat an injury no data collected
(1) To reduce inflammation/swelling 70.5%
(2) To treat an injury 48.3%
(3) To reduce muscle soreness 34.1
(4) To continue running through an injury 13.8%
(5) To increase pain tolerance 12.8%
(6) To treat chronic pain or ongoing medical issues -
no data collected.
Table 5 Awareness of Adverse Drug Reactions of NSAIDs (n = 779)
Adverse drug reaction n %
Cardiovascular events (e.g. heart attack) 335 43.0
Gastrointestinal damage (ulcers/ discomfort/ bleeding) 482 61.9
Kidney damage 330 42.4
Increased recovery time from exercise 24 3.1
Increased recovery time from injury 77 9.9
Not aware of any adverse drug reactions 85 10.9
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at the Hannover marathon suggested lower rates of use of
analgesic use (17%).[25]
Joslin and colleagues examined analgesic use in endur-
ance runners and found a similar use of NSAIDs by half-
marathon/marathon runners and ultramarathon runners
during training (59% versus 63%), but higher use of
NSAIDs during event, with 70% of ultra-runners using
NSAIDs compared to 26% of other runners.[26] Other
studies of ultra-runners have confirmed significant use of
NSAIDs,[13,27-30] along with studies of adventure racing[31]
and Ironman triathlon events.[11,32] This matches the high
usage of NSAIDs by endurance runners in our study, with
1 in 3 ultra-runners reporting taking NSAIDs during
events.
Reasons for NSAID use
Our study found NSAID usage was higher in injured
respondents. Running related injuries are more common
in new inexperienced runners.[33] Over half of Parkrun
UK attendees had a current injury in a recent study, and
the majority run through injuries, with novices more at
risk of injury.[34] Our study had a 70% prevalence of
injuries over the past 12 months, which could reflect the
type of runners who might respond to a survey on
NSAID use. However, running through an injury was a
common reason cited for use of NSAIDs in our study. In
addition, the age profile of our sample, and increased
chance of co-morbidities, may have made the use of
NSAIDs more likely.
Fifty-seven per cent of respondents answered yes to
taking an NSAID before a run/race, with little difference
between event length. This is similar to a study which
found 49% of runners took an NSAID immediately before
a marathon.[10] Other published figures include 38% of
runners taking an NSAID in the 2 weeks prior to a mara-
thon,[35] and 35% of ultramarathon runners and 13% of
marathon runners taking an NSAID in the 24 h preceding
a race.[18,36]
Overall 11% of our respondents said they had used an
NSAID during a race/run with rates of use increasing in
the groups that had participated in longer distance events.
Half-marathoners and marathon runners were roughly 4
times more likely to use NSAIDs than 10 km runner, but
ultramarathoners were 8 times more likely to use NSAIDs
during an event with 1 in 3 using NSAIDs during an
event. A culture of reliance on NSAIDs appears prevalent.
A study in professional triathletes found that NSAID
users had a high expectation of an anti-inflammatory
effect (79%) and an analgesic effect (64%). This is seen in
our data set with 58% of runners taking an NSAID before
a race/run, 51% during and 71% after a race/run expect-
ing it to reduce swelling or inflammation.
In our study, 42–54% of runners who would take an
NSAID before or during a race did so believing it would
increase pain tolerance, with 43–49% believing it would
allow them to continue running through an injury. In a
professional triathlete population, 62% of those that took
NSAIDs immediately before or during the race expected
that it would prevent pain during the race.[11] Our results
would tend to support Holgado and colleague’s position
that NSAIDs may be used by some for a perceived ergo-
genic benefit.[5]
We found no widespread use of NSAIDs outside of
their recommended dosages, compared to Kuster and col-
leagues who found over 1 in 4 users did so[10]; such run-
ners were 4–10 times more likely suffer adverse effects
during the event. Similar overuse was found during the
London Marathon.[24]
Low mileage runners in our study were using NSAID
for chronic pain, current injuries or ongoing medical
issues, suggesting the use of NSAIDs is to facilitate partic-
ipation in running activities. This suggests some recre-
ational runners are using NSAIDs chronically to enable
participation in exercise, despite possible increased risks
of long-term adverse effects associated with chronic dos-
ing such as cardiovascular events.[37] In contrast, higher
distance high endurance event runners, such as ultrama-
rathoners, are interested in the reduction of swelling/in-
flammation and reduction of muscle soreness.
This differential in use is of interest. Those engaged in
longer endurance events may be looking for an ergogenic
performance enhancement, including the reduction in
pain that might allow them to push harder during a race.
In contrast, more recreational runners may be seeing a
solution to maintain a minimum baseline physical activity
to preserve their health status. Therefore, NSAIDs may
provide a paradoxical dual role, in endurance runners
being tied to performance goals, but in recreational run-
ners as an enabler of a healthy activity.
There is currently interest in the prescribing of physical
exercise to maintain health status[38,39] and a willingness
from pharmacists to become involved in such social pre-
scribing.[40] Given the pharmacists’ role in the supply of
over-the-counter medicines, they may be well placed to
discuss the place of NSAIDs in enabling exercise, while
also reducing the risk of associated harms.
Adverse effects of NSAIDs
A quarter of runners in this study experienced a suspected
ADR over the prior 12 months, similar to an Olympic
and Paralympic study which found 19% reporting NSAID
related ADRs, with ibuprofen having lower reported
ADRs.[41] One in five of our NSAIDs users had a pre-ex-
isting contra-indication or caution to use of NSAIDs, yet
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still used NSAIDs either through ignorance or through
their own assessment of the benefit–harm balance.
NSAIDs are associated with serious ADRs[42] and are
responsible for 30% of hospital admissions due to adverse
drug reactions.[43] Co-use during physical activity carries
long established risks.[7] While runners may not be con-
sidered to have the risk factors that elderly non-athletic
patients have, our study shows the use of NSAIDs in
sport occurs outside of elite athletics in an increasingly
active older population.
The use of NSAIDs for short-term pain and soreness
relief may be to the detriment of long-term healing and
outcomes related to training[44] or allow an athlete to put
undue strain on an injury prematurely by the suppression
of pain.[45] NSAIDs may also affect bone consolidation,
potentially delaying healing or adding to the dangers of
stress fractures.[7] Since muscle regeneration is partly
dependent on prostaglandins, long-term NSAID use may
impair the adaptive response to exercise.[44]
There is therefore a balance to be struck between any
short-term benefits of NSAIDs on performance and pain,
versus a potentially reduced quality of healing or training
response. Concern exists that NSAID use increases health
risks for no or little benefit.[13]
Endurance runners
A subset of the runners in this study ran at marathon
length or higher, alongside their Parkrun UK activity.
Their high use of NSAIDs during longer endurance events
carries additional risk of more acute adverse effects such
as acute gastrointestinal haemorrhage,[10] acute renal
impairment[37] and hyponatraemia.[32]
During exercise, gastrointestinal blood flow is
reduced,[46] and gastrointestinal symptoms are common
in runners even in the absence of NSAIDs. Serious gas-
trointestinal bleeding associated with NSAID use has been
reported following a marathon,[10] and NSAID use has
been associated with endotoxaemia during an ultrama-
rathon.[12]
Reduced blood flow to the kidneys during exercise,
combined with the NSAID inhibition of renal prostaglan-
dins, has been associated with acute renal impairment
since the late 1970s.[47] Faster runners with higher weight
loss during the race are more at risk, suggesting dehydra-
tion is a risk factor.[37]
Exercise-associated hyponatraemia is associated with
overhydration and inappropriate secretion of arginine
vasopressin leading to water retention.[48] Water retention
is a known effect of NSAIDs and may increase the risk of
hyponatraemia. A statistically significant association
between NSAID use and hyponatraemia in Ironman
triathletes has been described.[32]
Informational requirements of runners
The awareness of the risk of ADRs was high in our study
(89.1%), in contrast to a study of marathon runners
which found 93% of runners were not informed of the
risk associated with NSAID use and exercise.[10] Other
studies have shown higher awareness of risk: a study of
professional triathletes which found awareness of gas-
trointestinal effects 59%, renal complications 27%, kidney
failure 18% and stomach bleeding 24%.[11] However, sig-
nificant numbers of NSAID users remain unaware of
some of the more serious adverse drug reactions associ-
ated with NSAIDs, and runners should be educated about
the particular risks associated with their use. For high
mileage and longer event runners, the most likely to use
NSAIDs during prolonged physical exertion, the acute
risks of exertional hyponatremia and acute kidney failure
during endurance events should be highlighted. For more
recreational and novice runners, the more long-term
health risks, such as cardiovascular disease, need to
explained clearly.
Our respondents would welcome further information
about the benefits and risks of using NSAIDS in combina-
tion with exercise. Patient information leaflets distributed
with NSAIDs do not provide specific information about
additional risks associated with exercise. Advice to ‘drink
according to thirst’ to prevent hyponatraemia has becom-
ing more common[49]; more explicit advice on the avoid-
ance of NSAIDs, particularly in longer duration events,
should follow. In recent years, the London Marathon
organisers have informed participants about the risks of
NSAIDs for the first time and advise avoidance of their
use within 48 h of the race.[50] The high level of NSAID
in longer endurance race runners we have found would
suggest this is reasonable advice.
Conclusion
Use of NSAIDs in this first study of recreational runners
is high and appears to be chronic in nature. Our rates of
self-reported use around race events are broadly in line
with previous studies of NSAID use in elite athletes.
NSAID use could be both a public health risk and a con-
founder in studies of the health effects of running.
While injury is, as expected, associated with NSAID
use, runners are also using NSAIDs to facilitate participa-
tion in events, to push through injuries by increasing pain
tolerance and to deal with post-event soreness. The high
usage of NSAIDs without full knowledge of adverse
effects, contra-indications or cautions for use, is of
concern. On the other hand, NSAIDs may be playing a
valuable role in enabling individuals participate in
exercise.
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The lack of evidence for benefits of NSAIDs in exercise
means some runners may be making poor benefit–harm
decisions. An unmet desire for information about NSAID
by recreational runners exists. Health professionals, par-
ticularly pharmacists in an over-the-counter setting,
should be aware of this subset of NSAID users. The use
of NSAIDs before races and during races by those under-
taking longer endurance events is concerning given the
greater physiological stresses of those events. Organisers
of longer endurance events should consider providing evi-
dence-based advice on the use of NSAIDs.
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